Atara Biotherapeutics Inc. (NASDAQ:ATRA) insider Mitchall G. Clark sold 2,995 shares of Atara Biotherapeutics stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $19.53, for a total value of $58,492.35. Following the sale, the insider now owns 98,182 shares of the company’s stock, valued at $1,917,494.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 18.05 on Monday. The firm’s market capitalization is $520.92 million. The firm has a 50-day moving average price of $16.82 and a 200-day moving average price of $19.56. Atara Biotherapeutics Inc. has a one year low of $12.45 and a one year high of $40.80.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Friday, November 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.10. Equities analysts anticipate that Atara Biotherapeutics Inc. will post ($3.05) earnings per share for the current year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in Atara Biotherapeutics during the third quarter worth approximately $110,000. BlackRock Group LTD increased its position in Atara Biotherapeutics by 3.7% in the third quarter. BlackRock Group LTD now owns 5,532 shares of the company’s stock worth $119,000 after buying an additional 198 shares during the last quarter. BlackRock Inc. increased its position in Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the last quarter. Institutional investors and hedge funds own 74.45% of the company’s stock.

Several equities analysts have issued reports on the company. Jefferies Group reiterated a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 10th. Citigroup Inc. lifted their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a report on Friday, August 19th. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Sunday, November 6th. Three analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $25.86.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.